Skip to content
Peptide research

PEG-MGF

Also known as PEGylated Mechano Growth Factor
Category
Tissue Repair & Recovery
Administration routes
Injectable
Regulatory status
Not FDA-approved

A PEGylated MGF-related peptide intended to prolong exposure; sustained muscle-repair effects after training have not been established. The case rests entirely on animal and cell studies, and one even found no effect on muscle stem cells. It has never been tested in a human trial, leaving essentially no human safety data and an unresolved, IGF-1-related tumor concern. Not an approved drug in the US; products sold online are unregulated and of uncertain purity.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

MGF (Mechano Growth Factor) is a natural repair peptide produced by your muscles, heart, and brain when tissue is damaged or mechanically stressed. PEG-MGF attaches polyethylene glycol to an MGF-related peptide with the aim of prolonging exposure. Its active life in humans has not been established.

How it works in the body

PEG-MGF modifies an MGF-related peptide with polyethylene glycol to try to prolong exposure. Satellite-cell effects reported for unpegylated MGF peptides are disputed and have not established sustained muscle-repair signaling with PEG-MGF.

Research overview

PEG-MGF research builds on three decades of work on MGF itself, spanning muscle repair, heart protection, nerve regeneration, and bone healing -- all in lab and animal studies only. Key findings include activation of muscle stem cells (Kandalla et al., 2011), 35% reduction in heart attack damage in sheep models (Carpenter et al., 2008), increased brain stem cell growth in aging mice (Tang et al., 2017), and faster tendon healing in rats. However, a critical 2014 study (Fornaro et al.) found no effect of MGF peptide on muscle cells, and a 2010 review noted that no endogenous MGF peptide has ever been isolated from actual tissues -- raising questions about whether the synthetic version mimics a real biological signal. No human clinical trials of PEG-MGF or native MGF have been published, and the field remains actively debated.

Who researches PEG-MGF?

Commonly researched by

  • People exploring muscle growth and performance

    Researched for potential effects on lean mass, strength, or athletic performance.

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those with Active cancer

    High

    Growth factor activity may promote tumor cell proliferation.

  • Those who are pregnant or breastfeeding

    Absolute

    No safety data. Growth factor modulation during pregnancy is dangerous.

Safety & interactions

Do not use if

  • Active cancer

    High

    Growth factor activity may promote tumor cell proliferation.

General cautions

  • Pregnancy

    Absolute

    No safety data. Growth factor modulation during pregnancy is dangerous.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • Never administered to humans in a controlled clinical trial

    High

    ClinicalTrials.gov / PubMed — no human MGF/PEG-MGF trials

  • Fornaro et al. 2014 found no effect of MGF peptide on myoblasts/muscle stem cells (efficacy debated)

    Moderate

    Fornaro et al. 2014, Am J Physiol Endocrinol Metab, PMID 24253050

  • IGF-1-related; could theoretically accelerate tumor proliferation

    Theoretical

    IGF-1R in cancer, PMC2361813; MGF IGF-1R-independence noted across MGF literature

  • Unregulated products sold online

    High

    Regulatory status: no FDA approval

  • Injection site pain/numbness/redness (anecdotal)

    Low

    Anecdotal user reports; no controlled safety data

  • May lower blood glucose; hypoglycemia risk with diabetes meds

    Theoretical

    IGF-1 glucose homeostasis/hypoglycemia, PMC508095; MGF glucose effect not demonstrated

Interaction summary(6)

Rated by direction with this peptide

  • Insulin and antidiabetic agents (sulfonylureas, insulin)

    CautionTheoretical

    IGF-1-family peptides can have insulin-like glucose-lowering effects that could in theory add to hypoglycemic drugs, though MGF E-peptide has no demonstrated glucose effect and acts largely independently of the IGF-1 receptor.

    IGF-1 glucose homeostasis, PMC508095

  • Corticosteroids / glucocorticoids

    CautionTheoretical

    Glucocorticoids suppress IGF-1/MGF anabolic signaling and drive muscle catabolism, so concurrent steroids would be expected to blunt MGF's intended muscle/tissue-repair effect (antagonistic to the goal).

    Glucocorticoid suppression of muscle IGF-1, ATS/AJRCCM ajrccm.159.1.9803021

  • Growth hormone / IGF-1 axis therapies (rhGH, secretagogues, rhIGF-1)

    SynergisticTheoretical

    GH induces endogenous muscle MGF splicing, so co-administration is theoretically additive on the IGF/MGF anabolic axis — which also compounds the theoretical IGF-related proliferative concern; no human interaction data exist.

    GH induces muscle MGF, PMC1665252

  • Testosterone / anabolic-androgenic steroids

    SynergisticTheoretical

    An additive hypertrophic effect with MGF/PEG-MGF is plausible mechanistically but has never been formally studied, and combined growth signaling is unquantified for safety.

    Mechanism; no controlled data

  • IGF-1R-targeted cancer therapy (anti-IGF-1R agents)

    CautionTheoretical

    Introducing an IGF-family growth peptide runs counter to the intent of IGF-axis-directed oncology treatment; caution is prudent even though MGF signals partly independently of the IGF-1 receptor.

    IGF-1R signaling in cancer, PMC2361813

  • Active or prior malignancy (clinical condition)

    CautionTheoretical

    A pro-proliferative, anti-apoptotic growth-factor peptide is theoretically undesirable in the setting of active or historical cancer; no data establish actual risk, but avoidance is the conservative default.

    IGF/growth-factor pro-proliferative biology, PMC2361813

Known risks(9)

  • No established human safety profile whatsoever

    High

    PEG-MGF has never been administered to humans in any controlled clinical trial. All safety data is extrapolated from animal studies using native MGF E-domain peptide. Long-term effects, appropriate dosing, pharmacokinetics in humans, and toxicity thresholds are entirely unknown.

  • Contested scientific basis for efficacy

    High

    Fornaro et al. 2014 found no effect of MGF peptide on myoblasts or muscle stem cells, and Matheny et al. 2010 noted no endogenous MGF E-peptide has been isolated from any tissue. The fundamental premise that synthetic MGF peptide recapitulates a physiological signal is unproven, meaning users may be injecting a peptide with no therapeutic activity.

  • Potential to promote abnormal cell growth or tumorigenesis

    High

    As a growth factor related to IGF-1, PEG-MGF could theoretically accelerate the proliferation of abnormal cells including pre-cancerous or cancerous tissue. IGF-1 signaling is implicated in multiple cancers. Those with active cancer, tumors, or cancer history should avoid PEG-MGF. Long-term oncogenic risk is completely uncharacterized.

  • Research-grade product purity and contamination concerns

    High

    Most PEG-MGF on the market is unregulated products sold online. Despite claims of 98-99% purity, there is no pharmaceutical-grade quality control, no GMP manufacturing requirement, and variable third-party testing. Impurities may include truncated peptides, aggregates, endotoxins, or incorrect PEGylation. PEGylation itself can trigger immunogenic reactions (anti-PEG antibodies) with repeated exposure.

  • Injection site reactions

    Low-Moderate

    Common anecdotal reports include pain, numbness, redness, swelling, and irritation at subcutaneous or intramuscular injection sites. PEGylated compounds are known to cause local inflammatory reactions.

  • Hypoglycemia risk (IGF-1-related)

    Moderate

    As an IGF-1 splice variant, PEG-MGF may lower blood glucose. Combined with diabetes medications, insulin, or in fasting states, this could cause dangerous hypoglycemia. Blood sugar should be monitored by anyone considering use.

  • Fatigue and flu-like symptoms

    Low-Moderate

    Anecdotal reports from self-experimenters include fatigue, flu-like symptoms, and general malaise, particularly at higher doses. These may relate to immune activation from the PEGylated peptide or metabolic shifts.

  • Muscle tightness, cramps, and water retention

    Low

    User reports include localized muscle tightness and cramping (possibly from localized growth factor activity) and temporary water retention. These effects are anecdotal and not characterized in controlled studies.

  • Hepatic and renal concerns

    Moderate

    PEG-MGF metabolism relies on liver and kidney function. Patients with hepatic or renal impairment need careful monitoring. PEGylated compounds are cleared renally, and accumulation in renal-impaired individuals is a known class concern.

Drug interactions(7)

  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)

    Theoretical additive hypoglycemia risk. PEG-MGF is derived from IGF-1, which has insulin-like glucose-lowering effects. Combined use could potentiate blood sugar reduction beyond intended levels. Blood glucose should be monitored closely.

  • Metformin and other diabetes medications

    Overlapping effects on glucose regulation. Both PEG-MGF (via IGF-1-related mechanisms) and metformin affect cellular energy metabolism. Blood sugar should be monitored more frequently with concomitant use. No clinical interaction data exists.

  • Growth hormone (GH) and GH secretagogues

    GH directly stimulates endogenous MGF expression in muscle tissue (Imanaka et al. 2008). Exogenous GH combined with exogenous PEG-MGF could create supraphysiological growth factor signaling with unpredictable anabolic and potentially oncogenic effects.

  • IGF-1 and IGF-1 analogs (mecasermin, IGF-1 LR3)

    Complementary but overlapping growth factor signaling. PEG-MGF and IGF-1/LR3 act through partially different pathways (MGF: ERK1/2; IGF-1: Akt/PI3K), but using them together compounds growth factor stimulation with unknown safety implications. No clinical safety data exist for this combination.

  • Glucocorticoids (prednisone, dexamethasone, cortisol)

    Corticosteroids inhibit muscle repair and promote catabolism, potentially antagonizing PEG-MGF's anabolic and repair-promoting effects. Concomitant glucocorticoid treatment may reduce PEG-MGF effectiveness.

  • Anticoagulants and blood thinners (warfarin, aspirin, heparin)

    May increase bruising at injection sites. Not a dangerous pharmacological interaction, but should be monitored for excessive bruising or hematoma formation at injection sites.

  • Immunosuppressants

    Theoretical concern -- PEG-MGF affects tissue repair and inflammatory signaling, and PEGylated compounds can modulate immune responses. May interfere with immunosuppressive drug efficacy or trigger unexpected immune reactions. No clinical data.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
85
Human Studies
0

The cited therapeutic evidence concerns native MGF, synthetic E-domain peptides, gene overexpression or peptide-loaded scaffolds. It is preclinical background and does not establish the effects of PEG-MGF itself. These studies used cell culture and animal models, including mice, rats, rabbits and sheep. Human data are limited to observational studies measuring endogenous MGF/IGF-1Ec mRNA expression in human muscle biopsies after exercise or injury, and in vitro studies using human-derived muscle progenitor cells treated with synthetic MGF peptide (Kandalla et al. 2011). No interventional human trial has administered PEG-MGF or MGF E-domain peptide to human subjects. The preclinical evidence is robust in cardiac protection models but actively contested in skeletal muscle (Fornaro et al. 2014 contradicted satellite cell activation claims). Anti-doping labs have developed detection methods for MGF (Thevis et al. 2014), indicating known illicit use in athletes despite absence of clinical validation.

Researched for(7)

Rated by confidence in the evidence

  • Muscle satellite cell activation and skeletal muscle repair

    Low

    Animal and cell studies suggest satellite cell activation, but one 2014 study found none. No human data.

    Hill & Goldspink 2003, J Anat, PMC1571137; contested by Fornaro 2014, PMID 24253050

  • Cardioprotection and reduced cardiac damage after myocardial infarction

    Low

    Consistent across mouse and sheep heart attack models, reducing cell death, with no human trials yet.

    Carpenter 2008 sheep MI PMID 17581790; Doroudian/Peña 2013 mouse MI E-domain PMID 23712705

  • Neuroprotection and promotion of neurogenesis in the aging brain

    Low

    Mouse studies show new neuron growth and reduced brain injury in aging models, no human data.

    Tang et al. 2017, Mol Brain, PMID 28683812 (neurogenesis, aging mouse)

  • Tendon repair and accelerated healing

    Low

    A rat Achilles study showed faster, stronger tendon healing, backed by a cell mechanism, no human data.

    Rat Achilles healing PMID 27334712; tenocyte migration FAK-ERK1/2 PMID 24434354

  • Cartilage protection and osteoarthritis modulation

    Low

    A rabbit knee arthritis model and cell studies show less cartilage breakdown, no human data.

    Rabbit knee OA model, Song 2018 PMID 28599103; chondrocyte hypoxia study PMID 34015701

  • Bone healing acceleration

    Low

    Rabbit bone-defect studies show faster healing, though effects may depend on stage, no human data.

    Rabbit bone-defect healing, Deng 2011 PMID 21057789 (counterpoint: MGF-E inhibits mineralization, S0003996911003967)

  • Extended half-life and sustained action vs native MGF

    Speculative

    Expected from PEGylation chemistry, but no published pharmacokinetic study of PEG-MGF itself exists.

    General PEGylation pharmacology; native MGF minutes-scale half-life — no primary PK study of PEG-MGF located

Benefits(7)

  • Muscle satellite cell activation and skeletal muscle repair

    Kandalla et al. 2011 (Mechanisms of Ageing and Development) -- MGF-24aa-E peptide significantly increased proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult human muscle, enhancing fusion potential for muscle repair. Goldspink 2005 demonstrated a 25% increase in mean muscle fiber size following single intramuscular MGF injection in mice. Note: Fornaro et al. 2014 (Am J Physiol) found no effect of MGF peptide concentrations up to 500 ng/ml on C2C12 cells or primary human myoblasts, creating significant scientific debate.

  • Cardioprotection and reduced cardiac damage after myocardial infarction

    Carpenter et al. 2008 (Heart Lung Circ) -- Intracoronary delivery of MGF E-domain in sheep preserved cardiac function with 35% less compromised cardiac muscle vs controls; caspase-3 immunostaining was absent in treated hearts. Mavrommatis et al. 2013 (Mol Cell Biochem) -- MGF E-domain peptide showed rapid nuclear uptake (IGF-1R independent), prevented mitochondrial dysfunction, blocked caspase-3 activation, and preserved cardiac contractility in mice post-MI. Pena et al. 2015 (Biomaterials) -- Localized MGF E-domain delivery via PEG microstructures achieved 100% survival at 2 and 10 weeks post-MI in mice vs 54-80% in controls.

  • Neuroprotection and promotion of neurogenesis in the aging brain

    Tang et al. 2017 (Molecular Brain) -- MGF overexpression significantly increased BrdU+ proliferative cells in the dentate gyrus and subventricular zone of the hippocampus in mice. Constitutive MGF overexpression starting at 1-3 months preserved olfactory function at 24 months. MGF enhanced number and size of neurospheres from neural stem cells in culture.

  • Tendon repair and accelerated healing

    Zhang et al. 2016 (Biotechnology Letters) -- Synthetic MGF-C25E peptide significantly improved Achilles functional index in rat injured tendons, with increased stiffness and superior macroscopic repair at 1000 ng/ml concentration. Histological analysis showed tissue remodeling and improved cell alignment.

  • Cartilage protection and osteoarthritis modulation

    Liu et al. 2023 (Acta Biochim Biophys Sin) -- Review showing MGF plays indispensable role in chondrocyte proliferation, migration, differentiation, inflammatory response, and apoptosis. Song et al. 2018 (J Tissue Eng Regen Med) -- MGF inhibited pathological apoptosis of OA chondrocytes and promoted proliferation, migration, and matrix synthesis via unfolded protein response regulation.

  • Bone healing acceleration

    A rabbit bone-defect study reported improved healing with unpegylated MGF-Ct24E, not PEG-MGF. PMID 25818452 concerns MGF/TGF-beta3 silk scaffolds for cartilage regeneration. These studies do not establish faster bone repair with PEG-MGF.

  • Intended prolonged exposure vs native MGF

    PEGylation is intended to prolong exposure, but a 48–72-hour PEG-MGF half-life has not been established by the clinical literature reviewed. Prolonged exposure is the primary rationale for PEG-MGF over unmodified MGF in research and clinical contexts.

Key studies(10)

  1. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages

    Original research (in vitro, human-derived cells)Primary human muscle cell cultures from neonatal, young adult, and old adult donorsVarious in vitro timepoints

    Kandalla PK, Goldspink G, Butler-Browne G, Mouly V

    Mechanisms of Ageing and Development

    2011

    MGF-24aa-E peptide significantly increased proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult muscle, and enhanced fusion potential across all age groups. Effect was absent in old adult muscle cells. Suggests therapeutic potential for sarcopenia without oncogenic risks of full IGF-1.

  2. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells

    Original research (in vitro, contradictory)C2C12 cells, primary human skeletal muscle myoblasts, primary mouse muscle stem cellsVarious in vitro assays

    Fornaro M, Hinken AC, Needle S, Hu E, Trendelenburg AU, Mayer A, Rosenstiel A, Chang C, Meier V, Billin AN, Becherer JD, Brace AD, Evans WJ, Glass DJ, Russell AJ

    American Journal of Physiology - Endocrinology and Metabolism

    2014

    Concentrations of MGF peptide up to 500 ng/ml failed to increase proliferation of C2C12 cells or primary human myoblasts, and failed to inhibit myoblast differentiation. No meaningful effects on primary mouse muscle stem cells or cellular signaling pathways. The authors concluded these findings 'call in to question whether there is a physiological role for MGF.'

  3. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction

    Original research (preclinical, ovine model)Sheep MI model (two experiments with vehicle, IGF-1, MGF E-domain, and full-length MGF groups)Acute MI followed by assessment eight days post-MI

    Carpenter V, Matthews K, Devlin G, Stuart S, Jensen J, Conaglen J, Jeanplong F, Goldspink P, Yang SY, Goldspink G, Bass J, McMahon C

    Heart Lung and Circulation

    2008

    Intracoronary delivery of MGF E-domain preserved cardiac function with 35% less compromised cardiac muscle than controls. Caspase-3 immunostaining was absent in MGF E-domain-treated hearts, indicating reduced apoptosis. The E-domain protected against ischemic damage independently and synergistically with mature IGF-1.

  4. The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction

    Original research (preclinical, murine model + in vitro)Mouse MI model and cultured cardiac cellsVarious timepoints post-MI

    Mavrommatis E, Shioura KM, Los T, Goldspink PH

    Molecular and Cellular Biochemistry

    2013

    MGF E-domain peptide demonstrated rapid cellular uptake and nuclear localization without activating IGF-1 receptors. In stressed cardiac cells, it prevented mitochondrial dysfunction and blocked caspase-3 activation. In vivo, it preserved cardiac contractility and reduced apoptotic cell death in viable myocardium post-MI.

  5. Localized Delivery of Mechano-Growth Factor E-domain Peptide via Polymeric Microstructures Improves Cardiac Function following Myocardial Infarction

    Original research (preclinical, murine model)Mouse MI model with PEG-based hydrogel microstructure delivery2 weeks and 10 weeks post-MI

    Pena JR, Pinney J, Ayala P, Desai T, Goldspink PH

    Biomaterials

    2015

    Localized MGF E-domain delivery via engineered PEG microstructures achieved 100% survival at 2 and 10 weeks post-MI (vs 54-80% in controls). Treatment decreased mortality, ameliorated hemodynamic decline, delayed decompensation, and inhibited pathologic hypertrophy.

  6. Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain

    Original research (preclinical, transgenic mouse model)Constitutive and conditional transgenic mouse models; neural stem cell culturesLongitudinal observation from 1-3 months to 24 months of age

    Tang JJ, Podratz JL, Lange M, Scrable HJ, Jang MH, Windebank AJ

    Molecular Brain

    2017

    MGF overexpression significantly increased BrdU+ proliferative cells in the dentate gyrus and subventricular zone. Early MGF enhancement (1-3 months) preserved olfactory function at 24 months. MGF increased quantity and size of neurospheres from neural stem cells in vitro. Suggests maintaining youthful MGF levels may counteract age-related neurological decline.

  7. Mechano-growth factor E peptide promotes healing of rat injured tendon

    Original research (preclinical, rat model)Rat Achilles tendon injury modelMultiple timepoints post-injury

    Zhang B, Luo Q, Kuang D, Ju Y, Song G

    Biotechnology Letters

    2016

    Synthetic MGF-C25E peptide significantly improved Achilles functional index in treated tendons vs saline controls. At 1000 ng/ml, treated tendons showed superior macroscopic repair, significantly increased stiffness, and histological evidence of tissue remodeling and cell alignment.

  8. Zablocka B, Goldspink PH, Goldspink G, Gorecki DC

    Frontiers in Endocrinology

    2012

    Reviewed MGF's roles in skeletal muscle satellite cell activation, cardiac protection post-MI, and neuroprotection. Highlighted that MGF has become a component of illicit anabolic/doping products despite limited mechanistic understanding and unproven human efficacy. Identified significant research gaps regarding endogenous E-domain peptide processing.

  9. Matheny RW Jr, Nindl BC, Adamo ML

    Endocrinology

    2010

    Critically noted that while synthetic MGF peptides promote cellular growth in vitro, 'no analogous peptide product of the Igf1 gene has been identified in or isolated from cultured cells, their conditioned medium, or in vivo animal tissues or biological fluids.' Raised fundamental questions about whether the synthetic MGF peptide represents a genuine physiological signal.

  10. Thevis M, Thomas A, Geyer H, Schanzer W

    Growth Hormone and IGF Research

    2014

    Identified and characterized a full-length MGF protein circulating through illicit channels. Developed immunoaffinity purification and mass spectrometry detection methods capable of detecting MGF at 0.25 ng/ml, enabling integration into routine anti-doping testing protocols.

Regulation & availability

Why researchers look at it

Studies of unpegylated MGF-related peptides report possible tissue-repair effects, with contradictory muscle-cell findings. They do not establish PEG-MGF's efficacy or duration of action. PEG-MGF is not FDA-approved; its former Category 2 nomination was withdrawn in April 2026 without establishing compounding eligibility.

Estimated cost
No approved product and no verified reference price
FDA status
PEG-MGF is not FDA-approved for any indication. Its former 503A Category 2 nomination was withdrawn in April 2026; it has not thereby become Category 1 or eligible for routine bulk compounding, and it is not on FDA's list of bulk substances pharmacies may use. FDA identifies immunogenicity and peptide-characterization concerns and no human-exposure data. FDA plans Pharmacy Compounding Advisory Committee consideration before the end of February 2027. Public records cannot establish that no confidential IND has ever been filed.
WADA status
PEG-MGF is prohibited at all times under WADA S2.3, which covers mechano growth factors and related analogues. A TUE requires an anti-doping organization's assessment against WADA's medical criteria; lack of marketing approval alone is not the stated categorical test. No PEG-MGF TUE indication was identified.
Prescribability
Not FDA-approved for any indication. PEG-MGF's former 503A Category 2 nomination was withdrawn in April 2026; this did not establish Category 1 status or lawful bulk-compounding eligibility, and it is not on FDA's list of bulk substances pharmacies may use. FDA retains its safety concerns and plans advisory-committee consideration before the end of February 2027. No established routine US prescription pathway was identified.
Availability
No approved PEG-MGF pharmaceutical product was identified. Some wellness clinics advertise it, but an offering does not establish lawful compounding or regulatory approval. Its former 503A Category 2 nomination was withdrawn in April 2026; withdrawal did not establish Category 1 status or a routine US bulk-compounding pathway. FDA's safety concerns remain. Pharmacies should not compound PEG-MGF, and there is no legitimate prescription pathway for it in the United States or any other country.

International status

  • EU

    Not approved

  • US

    PEG-MGF is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA plans to ask its advisory committee about adding it before the end of February 2027.

  • Australia

    Banned in sport (WADA)

Regulatory timeline(12)

  1. 1996
    Geoffrey Goldspink and colleagues at University College London first describe mechanically-induced IGF-1 splice variant expression in rabbit skeletal muscle, coining the term 'Mechano Growth Factor' (MGF).
  2. 2005
    Goldspink publishes key review on mechanical signals, IGF-I gene splicing, and muscle adaptation, establishing MGF as a distinct local tissue repair factor.
  3. 2008
    Carpenter et al. publish ovine MI study showing MGF E-domain preserves cardiac function with 35% less compromised muscle (Heart Lung Circ, PMID 17581790). Imanaka et al. show growth hormone stimulates MGF expression (Kobe J Med Sci, PMID 18772608).
  4. 2010-03
    Matheny et al. publish critical minireview in Endocrinology (PMID 20130113) noting no endogenous MGF E-domain peptide has been isolated from any biological tissue.
  5. 2011-04
    Kandalla et al. publish in Mechanisms of Ageing and Development (PMID 21354439) showing MGF-E activates human muscle progenitor cells and enhances fusion potential, but not in aged donors.
  6. 2012-10
    Zablocka et al. publish review 'MGF: important cog or loose screw?' in Frontiers in Endocrinology, warning that MGF has become a readily available doping product despite unproven human efficacy.
  7. 2014-01
    Fornaro et al. publish contradictory findings in Am J Physiol (PMID 24253050): MGF peptide has no effect on myoblasts or primary muscle stem cells at concentrations up to 500 ng/ml.
  8. 2014-12
    Thevis et al. develop mass spectrometric detection of full-length MGF for anti-doping controls (Growth Horm IGF Res, PMID 25466910), detecting MGF at 0.25 ng/ml.
  9. 2015-01
    Pena et al. publish localized MGF E-domain delivery study showing 100% survival at 10 weeks post-MI in mice via PEG microstructures (Biomaterials, PMID 25678113).
  10. 2017-07
    Tang et al. publish neurogenesis study in Molecular Brain (PMID 28683812) showing MGF promotes neural progenitor cell proliferation in the aging mouse hippocampus.
  11. 2023-09-29
    FDA places PEG-MGF on Category 2 interim list of bulk drug substances presenting significant safety risks under Section 503A, barring compounding pharmacies from producing it (among 19 total peptides restricted).
  12. 2026-03-29
    Subsequent update: FDA removed PEG-MGF from Category 2 following nomination withdrawal in April 2026. This did not establish compounding eligibility. FDA plans PCAC consideration before the end of February 2027.

Sources & FAQs

Research sources(19)

Frequently asked questions(5)

What is the difference between MGF and PEG-MGF?

MGF (Mechano Growth Factor) is the native splice variant of IGF-1 (known as IGF-1Ec in humans) that is produced locally in tissues after mechanical stress or injury. PEG-MGF attaches polyethylene glycol to an MGF-related peptide to prolong exposure. The stated native-MGF and PEG-MGF half-lives are not established human pharmacokinetic values.

How does PEG-MGF differ from IGF-1 LR3?

PEG-MGF and IGF-1 LR3 are both derived from the IGF-1 gene but have different structures and mechanisms. IGF-1 LR3 is a modified version of the mature IGF-1 peptide with a 13-amino-acid extension that reduces binding to IGF binding proteins, resulting in increased systemic IGF-1 activity. PEG-MGF contains the unique E-domain from the IGF-1Ec splice variant and appears to act through an IGF-1 receptor-independent mechanism, activating ERK1/2 but not Akt. PEG-MGF is thought to primarily activate satellite cells for local tissue repair, while IGF-1 LR3 promotes systemic anabolic effects.

Has PEG-MGF been tested in humans?

No. Neither PEG-MGF nor the native MGF E-domain peptide has been administered to humans in any published clinical trial. Human data is limited to observational studies measuring endogenous MGF/IGF-1Ec mRNA expression in muscle biopsies and in vitro studies using human-derived cells treated with synthetic MGF peptide. Despite widespread anecdotal use in bodybuilding and anti-aging communities, there is zero controlled human safety or efficacy data for PEG-MGF.

Is the scientific evidence for MGF's muscle-building effects actually solid?

The evidence is actively debated. The pro-MGF camp (led by Goldspink, Kandalla, Mouly) has shown satellite cell activation, increased proliferative lifespan, and muscle fiber hypertrophy in cell and animal models. However, Fornaro et al. (2014, Am J Physiol) found that MGF peptide at concentrations up to 500 ng/ml had no effect on C2C12 cells, primary human myoblasts, or primary mouse muscle stem cells. Matheny et al. (2010, Endocrinology) noted that no endogenous MGF E-domain peptide has ever been isolated from any tissue or biological fluid, questioning whether the synthetic peptide represents a real physiological signal. The field remains unresolved.

Is PEG-MGF legal to use?

PEG-MGF is not FDA-approved for human use and has no established routine US bulk-compounding pathway; its former Category 2 nomination was withdrawn in April 2026 without establishing Category 1 eligibility. It is prohibited by WADA under S2.3 (Growth Factors and Growth Factor Modulators). Self-administration is not sanctioned by any regulatory body and carries risks from uncharacterized product quality and unknown human safety profile.